MichaelJNaughtonMD

Clinical Trials

• Hormone Therapy With or Without Combination Chemotherapy in Treating Women Who Have Undergone Surgery for Node-Negative Breast Cancer (The TAILORx Trial) Start of enrollment: 2006 Apr 07

  Active, not recruiting

  Phase 3

• Effect of Neoadjuvant or Adjuvant Systemic Therapy on Breast Cancers, Bone Marrow Cancer Cells, and Circulating Cancer Cells Start of enrollment: 2005 Sep 14

  Recruiting

• Intensity Modulated Radiotherapy for Breast Cancer Start of enrollment: 2008 Jan 04

  Completed

  Phase 1

• Tamoxifen Citrate or Letrozole With or Without Bevacizumab in Treating Women With Stage IIIB or Stage IV Breast Cancer Start of enrollment: 2008 May 15

  Active, not recruiting

  Phase 3

• Paclitaxel, Nab-paclitaxel, or Ixabepilone With or Without Bevacizumab in Treating Patients With Stage IIIC or Stage IV Breast Cancer Start of enrollment: 2008 Oct 13

  Completed

  Phase 3

• Paclitaxel With or Without Carboplatin and/or Bevacizumab Followed by Doxorubicin and Cyclophosphamide in Treating Patients With Breast Cancer That Can Be Removed by Surgery Start of enrollment: 2009 May 15

  Active, not recruiting

  Phase 2

• A Phase III Randomized Trial of Metformin vs Placebo in Early Stage Breast Cancer Start of enrollment: 2010 Aug 13

  Completed

  Phase 3

• Tamoxifen Citrate, Letrozole, Anastrozole, or Exemestane With or Without Chemotherapy in Treating Patients With Invasive RxPONDER Breast Cancer Start of enrollment: 2011 Jan 15

  Active, not recruiting

  Phase 3

• Neratinib +/- Fulvestrant in Metastatic HER2 Non-amplified But HER2 Mutant Breast Cancer Start of enrollment: 2012 Dec 11

  Completed

  Phase 2

• S1207 Hormone Therapy With or Without Everolimus in Treating Patients With Breast Cancer Start of enrollment: 2013 Sep 12

  Active, not recruiting

  Phase 3

• Combining MLN8237 With Nab-Paclitaxel in Patients With Advanced Solid Malignancies Start of enrollment: 2013 May 07

  Completed

  Phase 1

• LDE225 in Treating Patients With Stage II-III Estrogen Receptor- and HER2-Negative Breast Cancer Start of enrollment: 2014 Apr 01

  Withdrawn

  Phase 2

• Effect of Trastuzumab on Disease Free Survival in Early Stage HER2-Negative Breast Cancer Patients With ERBB2 Expressing Disseminated Tumor Cells Start of enrollment: 2013 Dec 19

  Terminated

  Phase 2

• VEGFR/PDGFR Dual Kinase Inhibitor X-82 and Everolimus for Treating Patients With Pancreatic Neuroendocrine Tumors Start of enrollment: 2013 May 03

  Terminated

  Phase 1, Phase 2

• Paclitaxel and BKM120 Before Surgery in Treating Patients With Stage II or III Estrogen Receptor-Positive and HER2-Negative Breast Cancer Start of enrollment: 2014 Aug 01

  Withdrawn

  Phase 2

• Neoadjuvant Treatment of Triple Negative Breast Cancer Patients With Docetaxel and Carboplatin to Assess Anti-tumor Activity Start of enrollment: 2014 Jul 07

  Terminated

  Phase 2

• Join now to see all